Several clinical studies demonstrated that circulating leptin, TNF-α and IL-6 were significantly higher in patients with NAFLD/NASH, conversely adiponectin levels were significantly reduced in NAFLD/NASH patients66. This evidence concerns the gene ADIPOQ and metabolic dysfunction-associated steatotic liver disease.